Press release
August 3, 2026
Vertex Reports Second Quarter 2026 Financial Results
Vertex Pharmaceuticals Inc / Ma (VRTX)
— Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 billion — — Continued progress across research and development pipeline; povetacicept PDUFA date November 30th — — Entered into agreement to acquire